20220405_CP_CONITEC_006_2022_Exp_Ambrisentana
2022
20220405_CP_CONITEC_006_2022_Tec_Ambrisentana
20220407_CP_CONITEC_008_2022_PCDT_da_Esclerose
20220419_CP_CONITEC_009_2022_PCDT_do_Glaucoma
20220419_CP_CONITEC_010_2022_PCDT_Distrbio
20220426_CP_CONITEC_011_2022_Exp_Blinatumomabe
20220426_CP_CONITEC_011_2022_Tec_Blinatumomabe
20220426_CP_CONITEC_014_2022_Exp_Denosumabe
20220426_CP_CONITEC_014_2022_Tec_Denosumabe
20220426_CP_CONITEC_015_2022_Exp_Vacina
20220426_CP_CONITEC_015_2022_Tec_Vacina
20220426_CP_CONITEC_016_2022_Exp_acido
20220802_CP_CONITEC_042_2022_Exp_Cilgavimabe
20220802_CP_CONITEC_042_2022_Tec_Cilgavimabe.pdf
cp_conitec_041_2022_uso_de_limiares_anexos.pdf
20220802_CP_CONITEC_046_2022_Exp_Alfa-alglicosidase.pdf
20220802_CP_CONITEC_046_2022_Tec_Alfa-alglicosidase.pdf
Contribuições da Consulta Pública 48/2022 - Formulário Experiência ou Opinião - Dapagliflozina para tratamento de pacientes adultos com doença renal crônica em uso de terapia padrão